Premium
Evidence Required to Demonstrate Clinical Utility of Pharmacogenetic Testing: The Debate Continues
Author(s) -
Gillis N K,
Innocenti F
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.185
Subject(s) - pharmacogenetics , clinical pharmacology , medicine , clinical practice , genetic testing , medical physics , intensive care medicine , pharmacology , family medicine , biology , genotype , genetics , gene
Pharmacogenetics is an area of research that has potential to greatly benefit patients. However, the routine use of diagnostic pharmacogenetic testing to inform treatment decisions is limited. Here we discuss the determination of clinical utility of pharmacogenetic testing and the level of evidence required to support translation into clinical practice. Clinical Pharmacology & Therapeutics (2014); 96 6, 655–657. doi: 10.1038/clpt.2014.185